IFN-beta1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms.
Recently, mRNA encoding soluble isoforms of CD28 and CTLA-4 have been described in human lymphocytes. We demonstrate that interferon-beta1a (IFN-beta1a) can enhance the expression of these transcripts in human mononuclear cells. Because soluble CD28 and CTLA-4 molecules might affect T cell activation, our findings suggest an additional means whereby IFN-beta therapy might exert its immunomodulatory effects in multiple sclerosis (MS).
Giorelli
M
M
Department of Neurologic and Psychiatric Sciences, University of Bari, Bari, Italy. m.giorelli@tiscalinet.it
Livrea
P
P
Defazio
G
G
Ricchiuti
F
F
Pagano
E
E
Trojano
M
M
D000069594:Abatacept; D017398:Alternative Splicing; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000096:biosynthesis / Q000235:genetics*; D018106:CD28 Antigens / Q000096:biosynthesis / Q000235:genetics*; D060908:CTLA-4 Antigen; D002478:Cells, Cultured; D006801:Humans; D018796:Immunoconjugates; D016899:Interferon-beta / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology*; D009103:Multiple Sclerosis / Q000188:drug therapy; D020033:Protein Isoforms / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D015533:Transcriptional Activation
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D020033:Protein Isoforms; D012333:RNA, Messenger; D016899:Interferon-beta; D000069594:Abatacept